



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Disponible en ligne sur

ScienceDirect
www.sciencedirect.com

Elsevier Masson France

EM|consulte
www.em-consulte.com




IMAGE BANK

Impact of COVID-19 pandemic on an iris metastasis

Impact de la pandémie de COVID-19 sur une métastase irienne

S. Lemaître^{a,*}, R. Anguita^a, M.S. Sagoo^{a,b}

^a Ocular Oncology Service, Moorfields Eye Hospital NHS Foundation Trust, 162 City Rd, London EC1V 2PD, UK

^b National Institute for Health Research (NIHR) Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, UK

Available online 10 February 2021

A 41-year old Asian female undergoing systemic chemotherapy with Eribulin for metastatic breast cancer to regional lymph nodes, lung, bone and brain was diagnosed with a left iris and ciliary body metastasis (Fig. 1A). External beam radiotherapy (EBRT) to the eye and brain showed favourable iris tumour response (Fig. 1B). Unfortunately, systemic chemotherapy had to be discontinued 4 months after EBRT because of the COVID-19 pandemic. The left eye became progressively red and painful and examination showed a significant increase in the size of the lesion

which now took up over a third of the anterior chamber (Fig. 1C). Intraocular pressure was normal. Treatment options included further EBRT to the eye or brachytherapy. She was rapidly restarted on Eribulin which led to a significant regression of the uveal metastasis (Fig. 1D) and resolution of ophthalmic symptoms.

This case shows that careful observation is needed in ocular metastasis where treatment may be suspended for other reasons but a favourable outcome is possible by simply resuming previous treatment regimens.

* Corresponding author.

E-mail addresses: stefaniele@free.fr (S. Lemaître), r.anguitahenriquez@nhs.net (R. Anguita), mandeep.sagoo1@nhs.net (M.S. Sagoo).

<https://doi.org/10.1016/j.jfo.2021.02.002>

0181-5512/© 2021 Elsevier Masson SAS. All rights reserved.




Figure 1. A. Left iris and ciliary body metastasis diagnosed at the moment of chemotherapy treatment. B. Regression of the lesion following external beam radiotherapy. C. Recurrence of the metastasis after stopping chemotherapy because of the first wave of COVID-19 pandemic. D. Regression of the intraocular mass once chemotherapy was resumed.

Disclosure of interest

The authors declare that they have no competing interest. This manuscript has not previously been submitted for publication and has not been presented at a meeting.

All authors have contributed to project design, data collection or analysis, writing and/or revision of this manuscript.

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health, UK